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INVITED COMMENTARY
Michael S. Conte, MD, Boston, Mass
Over the last decade, attempts to identify and validate circu-
lating biomarkers predictive of cardiovascular disease have begun
to influence clinical practice, as well as to globally reshape thinking
on the pathophysiology of vascular events. Acute phase reactant
proteins, which classically reflect a response to acute injury or
infection, incorporate molecules with proinflammatory and proco-
agulant functions. Given the compelling evidence relating athero-
sclerosis to inflammation, the notion that circulating levels of such
molecules might be linked to the burden or activity of vascular
disease seems logical. For primary or secondary prevention pur-
poses, markers such as C-reactive protein offer utility in identifying
subgroups of patients at increased risk for long-term events, which
may be used to guide preventive nutritional, behavioral, and phar-
macologic therapies.1-3 Failure of vascular interventions, including
angioplasty, stenting, and surgical bypass, is a frequent problem
that clearly relates to the magnitude of the injury response. Iden-
tifying subgroups of patients at an elevated risk for aggressive
restenosis would be of great utility for the selection of optimal
interventions and quite possibly for guiding adjunctive medical or
other therapies to reduce the incidence of failure. To date, how-
ever, clinically useful biomarkers predictive of outcomes after
interventions have yet to be clearly identified. Data on the predic-
tive value of inflammatory markers in coronary interventions have
been conflicting, although one interesting study reported a bene-
ficial effect of targeted steroid therapy for patients with elevated
C-reactive protein levels after coronary stenting.4
Dr. Heider and colleagues have examined the levels of circu-
lating adhesion (E selectin, P selectin, soluble intercellular adhe-
sion molecule-1 (ICAM-1), and soluble vascular cell adhesion
molecule-1 (VCAM-1) and inflammatory monocyte chemoattrac-
tant protein-1 (MCP-1) molecules after peripheral interventions
for claudication in 44 subjects. The study is limited in assessing
predictive values by a small patient cohort, particularly since only
32 of these patients received interventions, among which were a
mixture of angioplasty alone and stenting. Heterogeneity among
this small group in lesion anatomy, comorbid risk factors, and
medical therapies further limits the ability to discriminate associa-
tions with the biomarkers. However, the authors were able to
provide important new data on the nature and time course of the
inflammatory response to peripheral catheter-based procedures.
Their results suggest that angiography per se engenders an inflam-
matory response and offer the possibility that certain markers (E
selectin, P selectin, and VCAM-1) may be predictive of poor
outcome. Much larger (and likely multicenter) studies will need to
be conducted to accurately identify and validate biomarkers for
adverse outcomes after peripheral endovascular interventions.
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